Deutsche Bank’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-69,244
| Closed | -$2.38M | – | 4639 |
|
|
2020
Q3 | $2.38M | Sell |
69,244
-96,755
| -58% | -$2.06M | ﹤0.01% | 1636 |
|
|
2020
Q2 | $2.77M | Sell |
165,999
-238,968
| -59% | -$4.06M | ﹤0.01% | 1610 |
|
|
2020
Q1 | $5.84M | Buy |
404,967
+72,787
| +22% | +$1.86M | 0.01% | 1167 |
|
|
2019
Q4 | $11.1M | Buy |
332,180
+137,224
| +70% | +$3.84M | 0.01% | 1038 |
|
|
2019
Q3 | $4.08M | Sell |
194,956
-20,068
| -9% | -$410K | ﹤0.01% | 1500 |
|
|
2019
Q2 | $4.47M | Buy |
215,024
+63,754
| +42% | +$1.31M | ﹤0.01% | 1888 |
|
|
2019
Q1 | $3.38M | Buy |
151,270
+55,895
| +59% | +$1.32M | ﹤0.01% | 2121 |
|
|
2018
Q4 | $2.28M | Sell |
95,375
-255,432
| -73% | -$6.61M | ﹤0.01% | 2310 |
|
|
2018
Q3 | $9.57M | Buy |
350,807
+50,442
| +17% | +$1.43M | ﹤0.01% | 1667 |
|
|
2018
Q2 | $8.08M | Sell |
300,365
-12,904
| -4% | -$395K | ﹤0.01% | 1922 |
|
|
2018
Q1 | $9.97M | Buy |
313,269
+93,452
| +43% | +$3.29M | ﹤0.01% | 1621 |
|
|
2017
Q4 | $8.31M | Sell |
219,817
-8,063
| -4% | -$260K | 0.01% | 1640 |
|
|
2017
Q3 | $5.65M | Buy |
227,880
+114,186
| +100% | +$2.46M | ﹤0.01% | 1837 |
|
|
2017
Q2 | $2.34M | Buy |
113,694
+36,472
| +47% | +$696K | ﹤0.01% | 2456 |
|
|
2017
Q1 | $1.68M | Sell |
77,222
-27,061
| -26% | -$555K | ﹤0.01% | 2363 |
|
|
2016
Q4 | $2.13M | Buy |
104,283
+22,346
| +27% | +$457K | ﹤0.01% | 2217 |
|
|
2016
Q3 | $1.23M | Buy |
81,937
+7,042
| +9% | +$95.1K | ﹤0.01% | 2692 |
|
|
2016
Q2 | $809K | Buy |
74,895
+69,105
| +1,194% | +$939K | ﹤0.01% | 3029 |
|
|
2016
Q1 | $78K | Buy |
5,790
+3,016
| +109% | +$47.1K | ﹤0.01% | 4144 |
|
|
2015
Q4 | $50K | Sell |
2,774
-300
| -10% | -$5.55K | ﹤0.01% | 4402 |
|
|
2015
Q3 | $77K | Buy |
+3,074
| New | +$71.9K | ﹤0.01% | 4217 |
|
Deutsche Bank's AIMT Position: Q4 2020 in Review
Deutsche Bank sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 69,244 shares — an estimated $2.38M sold.
Deutsche Bank first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $11.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Deutsche Bank reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Deutsche Bank sold 69,244 Aimmune Therapeutics shares in Q4 2020, an estimated $2.38M.
- Deutsche Bank first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Deutsche Bank's Aimmune Therapeutics position peaked at $11.1M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Deutsche Bank's 13F filing for Q4 2020, filed 16 Feb 2021.